Screening | BL | Acute phase | Follow-up | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Timepoint (week) | −2 | 0 | 1 | 3 | 5 | 7 | 8 | 10 | 12 | 22 | 34 |
Enrollment: | |||||||||||
Eligibility confirmation | x | ||||||||||
Informed consent | x | ||||||||||
Allocation | x | ||||||||||
Interventions: | |||||||||||
Minimal-contact CBT (MC-CBT) | X | T | X | T | X | X | |||||
UCPPS Education | X | T | X | T | X | X | |||||
Assessments: | |||||||||||
Primary outcome | |||||||||||
Global symptom improvement (CGI-I) | x | x | x | x | x | x | x | ||||
Secondary outcomes | |||||||||||
Emotional distress (BSI-18) | x | x | x | x | |||||||
Patient satisfaction (CSQ) | x | ||||||||||
Comorbid COPCs (CMSI) | x | x | x | x | |||||||
Pelvic pain severity (GUPI) | x | x | x | x | x | x | x | x | |||
Urinary problem severity (ICPI) | x | x | x | x | x | x | x | x | |||
Urinary symptom severity (ICSI) | x | x | x | x | x | x | x | x | |||
Pain interference (PPI SF-6a) | x | x | x | x | |||||||
Quality of life (SF-12 v2) | x | x | x | x | |||||||
Mediators | |||||||||||
Perspective broadening (CERQ-PB) | x | x | x | x | x | ||||||
Self-distancing (EQ-D) | x | x | x | x | x | ||||||
Perceived control (MAIA-2) | x | x | x | x | x | ||||||
Repetitive thinking (PTQ) | x | x | x | x | x | ||||||
Context sensitivity (CSI) | x | x | x | x | x | ||||||
Coping flexibility (CFS-R) | x | x | x | x | x | ||||||
Prescriptive predictors (moderators) | |||||||||||
Trait self-regulation (BRIEF-A) | x | ||||||||||
Prognostic predictors | |||||||||||
Comorbidities: medical and psychiatric | x | x | x | x | |||||||
Concomitant treatments | x | x | x | x | |||||||
Demographics, chronicity, etc. | x |